BioSpace News Archive

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, CEO and Founder will present a company overview at the Ophthalmology Futures Forums European Forum 2022 on September 15, 2022.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY ) and Regeneron Pharmaceuticals (Nasdaq: REGN ) announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH).

IN8bio, Inc. today announced it has selected the UofL Health - Brown Cancer Center GMP Manufacturing Facility at the University of Louisville, home of the Dunbar CAR T-Cell Program, as its manufacturing partner for INB-400.

Innovation Pharmaceuticals today announced that new Brilacidin antiviral data, based on research conducted by scientists at George Mason University’s Center for Infectious Disease Research (formerly NCBID), was presented at the 2022 Military Health System Research Symposium (MHSRS), held this week at the Gaylord Palms Resort and Convention Center, Kissimmee, FL.

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics, today announced presentations of preclinical data on the selective uptake of its hydroxyl dendrimer-based PET tracer, [18F]OP-801, in the spines of a murine model of multiple sclerosis and a reduction in the PET signal after treatment with a hydroxyl dendrimer therapeutic (HDT) that inhibits CSF1 receptors.

Daré Bioscience, Inc. today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two upcoming conferences.

Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced that senior management will participate in the UBS Biotechnology Private Company Virtual Symposium, being held September 21-22, 2022.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. Katharine Knobil to its Board of Directors, effective immediately.

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of September 2022, which is payable on October 17, 2022 to shareholders of record at the close of business on September 30, 2022.

Inhibikase Therapeutics, Inc. today announced that it will present safety, tolerability, pharmacokinetics and exploratory Parkinson’s assessment data from the Company’s Phase 1/1b ‘101' study of IkT-148009 in Parkinson’s disease at the International Congress of Parkinson’s Disease and Movement Disorders tomorrow, September 16th, 2022.